Qt Vascular Ltd (QTVLF) 0.0680 $QTVLF
QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States
PR Newswire - Mon Apr 25, 11:31AM CDT
QT Vascular Ltd. (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today it has submitted an investigational device exemption ("IDE" for permission to begin the pivotal study of Chocolate Touch(TM), its drug-coated balloon, in the United States ("US" .
QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
PR Newswire - Wed Feb 10, 8:07PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group" , is pleased to provide an update in its ongoing litigation with AngioScore, Inc. ("ÄngioScore" (now owned by Spectranetics Corporation (NASDAQ: SPNC)).
SPNC: 19.17 (+0.08)
QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon
PR Newswire - Thu Jan 07, 5:00AM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.
Update On AngioScore Litigation
PR Newswire - Mon Nov 30, 2:46PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, is pleased to announce that a three-judge panel of the United States Court of Appeals for the Federal Circuit ("Federal Circuit" has unanimously granted the Group and Dr. Eitan Konstantino ("Defendants" a motion to stay the enforcement of the trial court's judgment (being damages of US$20.034 million awarded against the Defendants) ("Trial Court's Judgement" on the State Law Claims ("Order" . The Defendants argued that a stay of enforcement was appropriate based on a four factor test that includes consideration of the likelihood of success on the merits of the appeal. AngioScore, Inc. ("AngioScore" had opposed the motion to stay the enforcement of the Trial Court's Judgement.
QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch
PR Newswire - Mon Oct 05, 6:20PM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today the release of the interim results from ENDURE, the first study of its unique peripheral drug-coated balloon, Chocolate Touch.
QT Vascular Announces Positive Outcome in Spectranetics/AngioScore Patent Trial
PR Newswire - Wed Sep 30, 8:30AM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, is pleased to announce that, following a seven-day jury trial before an Oakland jury sitting in the United States District Court for the Northern District of California, it has prevailed on the Patent lawsuit filed by AngioScore (now owned by Spectranetics Corporation (NASDAQ: SPNC)) ("Plaintiff" in 2012. The jury returned a unanimous verdict that the Chocolate® PTA does not infringe any of the asserted claims of United States Patent No. 7,691,119 ("'119 patent" ("Patent Claim" . Furthermore, the jury determined that all asserted claims of the '119 patent are invalid as obvious over the prior art.
SPNC: 19.17 (+0.08)
Jury in Federal Court in California Finds Against AngioScore's Patent Infringement Claims
GlobeNewswire - Wed Sep 30, 8:00AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that a jury in the U.S. District Court for the Northern District of California has found against its wholly-owned subsidiary, AngioScore Inc., the plaintiff in a lawsuit seeking damages and other relief for patent infringement against defendants Eitan Konstantino, TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. related to defendants' Chocolate PTA balloon catheter. The jury also found that certain claims of the asserted patent are invalid.
SPNC: 19.17 (+0.08)
QT Vascular Announces CE Mark Clearance Of Chocolate® Touch By LRQA 0088
PR Newswire - Tue Sep 08, 12:47PM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that has received CE mark clearance for its unique peripheral drug-coated balloon, Chocolate® Touch. The CE mark was granted by Lloyds Register Quality Assurance Notified Body Number 0088 ("LRQA 0088" .
QT Vascular Announces The Allowance Of Four New Patents
PR Newswire - Tue Jul 14, 1:28PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that the United States Patent and Trademark Office ("USPTO" has issued allowance letters of four (4) fundamental patents critical to its unique portfolio of specialty balloons for the treatment of vascular disease in coronary and peripheral vessels. Three of the patents cover the Group's flagship platform, Chocolate®, while the fourth patent covers the Group's Glider(TM) family of products.
QT Vascular Ltd. - AngioScore Litigation Additional Updates
PR Newswire - Wed Jul 08, 2:10AM CDT
Further to the Company's announcement of 29 April 2015 and 2 July 2015, and media release of 4 May 2015, the Board of Directors of the Company ("Board" would like to provide the following additional updates to shareholders of the Company in relation to the lawsuit filed by AngioScore, namely the State Law Claims and Patent Claim:
Global Cardiac Prosthetic Devices (Prosthetic Heart Valves and Coronary Stents) Market 2015-2019 - Rise in Birth Prevalence of Congenital Heart Disease Worldwide
M2 - Wed Jun 24, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/672rjb/global_cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market 2015-2019" report to their offering. The global cardiac prosthetic market to grow at a CAGR of 8.41% over the period 2014-2019. Prosthetic devices are used to replace or support the function of a missing or infirm part in the body. Cardiac prosthetic devices such as stents and prosthetic heart valves are used to maintain the proper functionality of the heart. Stents are used to maintain the blood flow, which reduces due to blockage in the arteries, whereas prosthetic heart valves are being used by patient with heart valvular disease or dysfunctional heart valve. The use of low-profile coronary stents has the potential to simplify the delivery system and increase the number of suitable candidates for endovascular repair. This is mainly because of their accuracy in placement, ease of use, and effectiveness in navigational challenges that occur during repair. Aortic stents have a diameter of 18 to 22 Fr. There are new technically advanced stents that have an outer diameter of less than 16 Fr. These low-profile stents are smooth and soft, which enables accurate device deployment and fulfills the need for a smaller-diameter delivery system to treat patients with inadequate access to limb vessels. According to the report, congenital heart disease is defined as a defect in the structure of the heart and the great vessels that are present at the time of birth. Defects can exist in the form of obstruction in blood flow or the flow of blood in an abnormal pattern. According to the JACC, there are 1.35 million newborns with congenital heart disease every year worldwide. It is estimated that eight per 1,000 live births are affected by congenital heart disease. In addition, congenital heart disease is responsible for 4.2% of all neonatal deaths. Further, the report states that a rise in complications and the need for re-intervention with stents are hindering the growth of the market. Key vendors - Boston Scientific - Edwards Lifesciences - Medtronic - Sorin Group - St. Jude Medical Other prominent vendors - AorTech International - Abbott Vascular - Accellent - Admedes Schuessler - Alvimedica - Arbor Surgical - B. Braun Melsungen - Biosensors International - Biotronik - Boston Scientific - Bracco AMT - Colibri Heart Valve - Elixir Medical - eucatech - Eurocor - Hexacath - InspireMD - InSitu Technologies - iVascular - LEPU MEDICAL - Meril Life Sciences - Merit Medical - OrbusNeich - QT Vascular - Rontis - SCITECH - Shanghai MicroPort Scientific - STENTYS - Svelte Medical Systems - Symetis - Translumina For more information visit http://www.researchandmarkets.com/research/67...al_cardiac
BSX: 22.63 (-0.12), MDT: 83.72 (+0.40), STJ: 77.89 (-0.26), MDSY: 1.60 (+0.20), EW: 101.50 (-0.03)
QT Vascular Announces First Patients Enrolled In Clinical Study Of Chocolate Touch(TM) PTCA Coronary Drug-Coated Balloon
PR Newswire - Wed May 20, 6:14PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group" , a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced it has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch(TM) PTCA (Coronary Drug Coated Chocolate®) in the Dominican Republic.
QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group" , a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.
QT Vascular Submits IDE Requesting Permission to Begin Pivotal Trial of Its Drug-Coated Chocolate Balloon in The United States
PR Newswire - Mon Apr 25, 11:31AM CDT
QT Vascular Ltd. (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today it has submitted an investigational device exemption ("IDE" for permission to begin the pivotal study of Chocolate Touch(TM), its drug-coated balloon, in the United States ("US" . QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
PR Newswire - Wed Feb 10, 8:07PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, is pleased to provide an update in its ongoing litigation with AngioScore, Inc. ("ÄngioScore" (now owned by Spectranetics Corporation (NASDAQ: SPNC)). SPNC: 19.17 (+0.08)
QT Vascular Announces Clinical Outcomes of Its Chocolate Heart Drug Coated Coronary Balloon
PR Newswire - Thu Jan 07, 5:00AM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart. Update On AngioScore Litigation
PR Newswire - Mon Nov 30, 2:46PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, TriReme Medical LLC and Quattro Vascular Pte. Ltd., collectively the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, is pleased to announce that a three-judge panel of the United States Court of Appeals for the Federal Circuit ("Federal Circuit" has unanimously granted the Group and Dr. Eitan Konstantino ("Defendants" a motion to stay the enforcement of the trial court's judgment (being damages of US$20.034 million awarded against the Defendants) ("Trial Court's Judgement" on the State Law Claims ("Order" . The Defendants argued that a stay of enforcement was appropriate based on a four factor test that includes consideration of the likelihood of success on the merits of the appeal. AngioScore, Inc. ("AngioScore" had opposed the motion to stay the enforcement of the Trial Court's Judgement. QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch
PR Newswire - Mon Oct 05, 6:20PM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today the release of the interim results from ENDURE, the first study of its unique peripheral drug-coated balloon, Chocolate Touch. QT Vascular Announces Positive Outcome in Spectranetics/AngioScore Patent Trial
PR Newswire - Wed Sep 30, 8:30AM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, is pleased to announce that, following a seven-day jury trial before an Oakland jury sitting in the United States District Court for the Northern District of California, it has prevailed on the Patent lawsuit filed by AngioScore (now owned by Spectranetics Corporation (NASDAQ: SPNC)) ("Plaintiff" in 2012. The jury returned a unanimous verdict that the Chocolate® PTA does not infringe any of the asserted claims of United States Patent No. 7,691,119 ("'119 patent" ("Patent Claim" . Furthermore, the jury determined that all asserted claims of the '119 patent are invalid as obvious over the prior art. SPNC: 19.17 (+0.08)
Jury in Federal Court in California Finds Against AngioScore's Patent Infringement Claims
GlobeNewswire - Wed Sep 30, 8:00AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that a jury in the U.S. District Court for the Northern District of California has found against its wholly-owned subsidiary, AngioScore Inc., the plaintiff in a lawsuit seeking damages and other relief for patent infringement against defendants Eitan Konstantino, TriReme Medical, LLC, Quattro Vascular Pte Ltd. and QT Vascular Ltd. related to defendants' Chocolate PTA balloon catheter. The jury also found that certain claims of the asserted patent are invalid.
SPNC: 19.17 (+0.08)
QT Vascular Announces CE Mark Clearance Of Chocolate® Touch By LRQA 0088
PR Newswire - Tue Sep 08, 12:47PM CDT
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that has received CE mark clearance for its unique peripheral drug-coated balloon, Chocolate® Touch. The CE mark was granted by Lloyds Register Quality Assurance Notified Body Number 0088 ("LRQA 0088" . QT Vascular Announces The Allowance Of Four New Patents
PR Newswire - Tue Jul 14, 1:28PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announced today that the United States Patent and Trademark Office ("USPTO" has issued allowance letters of four (4) fundamental patents critical to its unique portfolio of specialty balloons for the treatment of vascular disease in coronary and peripheral vessels. Three of the patents cover the Group's flagship platform, Chocolate®, while the fourth patent covers the Group's Glider(TM) family of products. QT Vascular Ltd. - AngioScore Litigation Additional Updates
PR Newswire - Wed Jul 08, 2:10AM CDT
Further to the Company's announcement of 29 April 2015 and 2 July 2015, and media release of 4 May 2015, the Board of Directors of the Company ("Board"
would like to provide the following additional updates to shareholders of the Company in relation to the lawsuit filed by AngioScore, namely the State Law Claims and Patent Claim: Global Cardiac Prosthetic Devices (Prosthetic Heart Valves and Coronary Stents) Market 2015-2019 - Rise in Birth Prevalence of Congenital Heart Disease Worldwide
M2 - Wed Jun 24, 5:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/672rjb/global_cardiac) has announced the addition of the "Global Cardiac Prosthetic Devices Market 2015-2019" report to their offering. The global cardiac prosthetic market to grow at a CAGR of 8.41% over the period 2014-2019. Prosthetic devices are used to replace or support the function of a missing or infirm part in the body. Cardiac prosthetic devices such as stents and prosthetic heart valves are used to maintain the proper functionality of the heart. Stents are used to maintain the blood flow, which reduces due to blockage in the arteries, whereas prosthetic heart valves are being used by patient with heart valvular disease or dysfunctional heart valve. The use of low-profile coronary stents has the potential to simplify the delivery system and increase the number of suitable candidates for endovascular repair. This is mainly because of their accuracy in placement, ease of use, and effectiveness in navigational challenges that occur during repair. Aortic stents have a diameter of 18 to 22 Fr. There are new technically advanced stents that have an outer diameter of less than 16 Fr. These low-profile stents are smooth and soft, which enables accurate device deployment and fulfills the need for a smaller-diameter delivery system to treat patients with inadequate access to limb vessels. According to the report, congenital heart disease is defined as a defect in the structure of the heart and the great vessels that are present at the time of birth. Defects can exist in the form of obstruction in blood flow or the flow of blood in an abnormal pattern. According to the JACC, there are 1.35 million newborns with congenital heart disease every year worldwide. It is estimated that eight per 1,000 live births are affected by congenital heart disease. In addition, congenital heart disease is responsible for 4.2% of all neonatal deaths. Further, the report states that a rise in complications and the need for re-intervention with stents are hindering the growth of the market. Key vendors - Boston Scientific - Edwards Lifesciences - Medtronic - Sorin Group - St. Jude Medical Other prominent vendors - AorTech International - Abbott Vascular - Accellent - Admedes Schuessler - Alvimedica - Arbor Surgical - B. Braun Melsungen - Biosensors International - Biotronik - Boston Scientific - Bracco AMT - Colibri Heart Valve - Elixir Medical - eucatech - Eurocor - Hexacath - InspireMD - InSitu Technologies - iVascular - LEPU MEDICAL - Meril Life Sciences - Merit Medical - OrbusNeich - QT Vascular - Rontis - SCITECH - Shanghai MicroPort Scientific - STENTYS - Svelte Medical Systems - Symetis - Translumina For more information visit http://www.researchandmarkets.com/research/67...al_cardiac
BSX: 22.63 (-0.12), MDT: 83.72 (+0.40), STJ: 77.89 (-0.26), MDSY: 1.60 (+0.20), EW: 101.50 (-0.03)
QT Vascular Announces First Patients Enrolled In Clinical Study Of Chocolate Touch(TM) PTCA Coronary Drug-Coated Balloon
PR Newswire - Wed May 20, 6:14PM CDT
QT Vascular Ltd., together with its subsidiaries ("QT Vascular" or the "Group"
, a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, today announced it has enrolled the first 11 patients in its First-In-Human (FIH) study of its novel Chocolate Touch(TM) PTCA (Coronary Drug Coated Chocolate®) in the Dominican Republic. QT Vascular Announces Acquisition of Novel Technology for Interventional Treatment
PR Newswire - Thu Oct 23, 10:05AM CDT
Catalist-listed QT Vascular Ltd. ("QT Vascular" or together with its subsidiaries, "the Group"
, a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel. 
